Enhancing Oncology Model: Revenue Impact for Practice Owners
The Enhancing Oncology Model is a voluntary Medicare value-based payment model for oncology practices that treat patients receiving systemic cancer therapy. For practice owners, participation can change how revenue arrives, what costs the practice carries and how much variability appears in its financial statements.
Those changes matter beyond the clinic. When a practice applies for financing, lenders look closely at the stability and predictability of cash flow, and value-based payments can add a layer of uncertainty that owners should be ready to explain. This article focuses on the financial side of participation. Model terms, eligibility and payment methods are set by Medicare and may change, and nothing here is legal, tax, billing, clinical or compliance advice. Qualified billing and compliance professionals should review participation decisions.
What the Model Is Designed to Do
The model aims to improve care coordination and manage the total cost of care during treatment episodes for certain cancers. Participating practices generally commit to providing enhanced services, which may include:
- Patient navigation and care coordination
- Comprehensive care planning
- Expanded access to clinicians outside regular office hours
- Screening for social needs that may affect treatment
- Use of data to drive quality improvement
In exchange, participants may receive additional payments for enhanced services and may share in savings or owe repayments depending on how actual episode spending compares with targets and how the practice performs on quality measures.
How the Enhancing Oncology Model Can Affect Revenue
From a financial perspective, participation may create several new revenue and cost patterns:
- Enhanced services payments: additional per-patient payments intended to support required services
- Performance-based payments: potential payments if spending and quality targets are met
- Potential repayments: obligations to return money if spending exceeds targets under applicable risk arrangements
- Added operating costs: staff for navigation, data analysis and reporting
Because performance results are typically reconciled after the fact, a practice may not know its final financial outcome for a period until well after the care was delivered.
Cash Flow Timing and Variability
The timing difference between when services are provided and when performance results are settled is an important consideration. A practice may invest in staffing and technology throughout the year while reconciliation payments or repayments arrive later.
That pattern can make year-over-year earnings look uneven. Owners should track model-related revenue and expenses separately so they can explain swings to accountants, partners and lenders. A practice with a potential repayment obligation may also want to set aside reserves rather than treating all model revenue as available cash.
Interaction With Drug Spending
Drug costs make up a large share of total spending in many cancer treatment episodes. Because the model looks at total cost of care, prescribing patterns and site-of-care decisions may affect performance results. Clinical decisions must always be made by physicians based on patient needs; this article addresses only the financial reporting side.
Drug spending also drives working capital needs through buy-and-bill purchasing. Our guide to oncology buy-and-bill cash flow covers that separate but related pressure.
How Lenders May View Value-Based Revenue
Lenders generally underwrite to historical, documented cash flow. When part of a practice’s revenue comes from a value-based model, lenders may ask:
- How much revenue comes from model payments versus fee-for-service
- Whether the practice has received performance payments or owed repayments in past periods
- What reserves exist for potential repayment obligations
- How the practice would perform if it left the model or if the model changed
Clear separation of model revenue in financial statements can help a lender assess these questions. Our article on oncology practice loan requirements covers what lenders review more broadly, and our article on oncology practice payer mix discusses Medicare concentration.
Impact on Practice Valuation
For buyers and sellers, model participation can complicate valuation. Appraisers may normalize earnings to separate recurring revenue from one-time performance payments, and they may consider the uncertainty of future model terms. Our article on oncology practice valuation explains how earnings are normalized. Participation agreements should not be assumed to transfer in a sale, and counsel should review them.
Planning for Working Capital
Because model-related investments come before potential payments, practices may need additional working capital to support navigation staff, technology and reporting. A revolving line can help bridge timing differences. Our oncology working capital lines of credit and broader working capital solutions may help practices manage these needs. Every loan is subject to approval, and nothing here is a commitment to lend.
Weighing Participation in the Enhancing Oncology Model
Deciding whether to participate, or whether to continue, is a business decision as well as a clinical one. Owners may want to model several scenarios: strong performance, results near target and results that trigger repayment. Comparing the added staffing and technology costs against the range of possible payments can show how much risk the practice is taking on. Accountants and advisors familiar with value-based arrangements can help build and test those scenarios.
Questions for Practice Owners
- Do our financial statements separate model revenue and costs?
- Do we have reserves for potential repayment obligations?
- How would our cash flow look without model payments?
- Have we reviewed participation terms with qualified compliance professionals?
Final Thoughts
The Enhancing Oncology Model can bring additional resources for care coordination, but it also introduces timing differences, performance risk and new costs that affect how a practice’s finances look to partners, buyers and lenders. Tracking model activity separately and planning working capital accordingly can help owners participate with a clear view of the financial impact.
US Medical Funding helps oncology practices finance operations, growth and transitions. Learn more about our full range of oncology practice financing options.
